Alzheimer's Disease
NEJM 314:964-973, Katzman,R., 1986
Studies in Aging of the Brain:IV. Familial Alzheimer Dis. :Relat. to Transmiss. Demetia, Aneuploidy, & Microtubular Defects
Neurol 29:1402, Book,R.H.,et al, 1979
Possible Biochemical Basis of Memory Disorder in Alzheimer Disease
Ann Neurol 3:471, Smith,C.M.,et al, 1978
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on 18F-Florbetapir PET Using ADNI Data
AJNR 41:980-986, Reith, F.,et al, 2020
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Memantine for Dementia in Adults Older than 40 years with Downs Syndrome (MEADOWS): a Randomised,double-blind,placebo-controlled Trial
Lancet 379:528-536, Hanney,M.,et al, 2012
Subjective Cognition and Amyloid Deposition Imaging
Arch Neurol 69:223-229, Perrotin,A.,et al, 2012
Visuospatial deficits in posterior cortical atrophy: structural and functional correlates
JNNP 83:860-863,855, Andrade, K.,et al, 2012
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
Neurodegenerative causes of death among retired National Football League Players
Neurol 79:1970-1974, Lehman, E.,et al, 2012
Longitudinal Assessment of A-beta and Cognition in Aging and Alzheimer Disease
Ann Neurol 69:181-192, Villemagne,V.L.,et al, 2011
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
In Vivo Mapping of Amyloid Toxicity in Alzheimer Disease
Neurol 72:1504-1511, Frisoni,B.G.,et al, 2009
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Positron Emission Tomography in Diagnosis of Visual Variant Alzheimer Disease
J Neuro-Ophthalmol 29:149-150, Finelli,P.F., 2009
Conversion of Amyloid Positive and Negative MCI to AD over 3 Years: An 11C-PIB PET Study
Neurol 73:754-760, 744, Okello,A.,et al, 2009
Pittsburg Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
Arch Neurol 66:1469-1475, Morris,J.,et al, 2009
Assessment of �-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography with Carbon 11-Labeled Pittsburgh Compound B
Arch Neurol 65:1304-1309,1281, Leinonen,V.,et al, 2008
A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
Arch Neurol 65:1509-1517, Aizenstein,H.J.,et al, 2008
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
The Woman Who Needed a Pet
Surv Ophthalmol 51:592-595, Atchison,M.,et al, 2006
Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy
Arch Neurol 62:721-728, Mega,M.S.,et al, 2005
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Low Blood Pressure and Risk of Dementia in the Kungsholmen Project
Arch Neurol 60:223-228, Qiu,C.,et al, 2003
Memantine in Moderate-to-Severe Alzheimer's Disease
NEJM 348:1333-1341, Reisberg,B.,et al, 2003
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
The Topography of Metabolic Deficits in Posterior Cortical Atrophy (the Visual Variant of Alzheimers Disease) with FDG-PET
JNNP 74:1521-1529, Nestor,P.J.,et al, 2003
Effect of Donepezil on Brain Acetylcholineserase Activity in Patients with AD Measured by PET
Neurol 56:408-410, Shinotoh,H.,et al, 2001
Stem-Cell Research: Drawing the Line
Lancet 358:163,217, Greenberg,D.S., 2001
Positron Emission Tomography in Evaluation of Dementia
JAMA 286:2120-2127,2194, Silverman,D.H.S.,et al, 2001
The Effect of Brain Atrophy on Cerebral Hypometabolism in the Visual Variant of Alzheimer Disease
Arch Neurol 58:480-486, Bokde,A.L.W.,et al, 2001
Progressive Aphasia with Rapidly Progressive Dementia in a 49 Year Old Woman
JNNP 66:238-243, Greene,J.D.W.,et al,, 1999
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
A Clinical Role for 99mTC-HMPAO SPECT in the Investigation of Dementia
JNNP 64:306-313, Talbot,P.R.,et al, 1998
Preclinical Prediction of Alzheimer's Disease Using SPECT
Neurol 50:1563-1571, Johnson,K.A.,et al, 1998
Measurement of Acetylcholinesterase by PET in the Brains of Healthy Controls & Pts with Alzheimer's Disease
Lancet 349:1805-1809, Iyo,M.,et al, 1997
Dementia in a 58-year-old Woman
Lancet 347:236, Sellal,F.,et al, 1996
Assessment of Brain SPECT:Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 46:278-285, , 1996